{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=33",
    "query": {
      "condition": "Phase 1",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 18606,
    "total_pages": 1861,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T20:57:33.027Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02012920",
      "title": "A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Castration-resistant Prostate Cancer",
        "CRPC"
      ],
      "interventions": [
        {
          "name": "Seviteronel: given orally once daily in 28 day cycles",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innocrin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 200,
      "start_date": "2011-12",
      "completion_date": "2019-01",
      "has_results": false,
      "last_update_posted_date": "2019-02-01",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 19,
      "location_summary": "Homewood, Alabama • Tampa, Florida • Jeffersonville, Indiana + 16 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Jeffersonville",
          "state": "Indiana"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02012920"
    },
    {
      "nct_id": "NCT07673120",
      "title": "A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ABBV-313",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 64,
      "start_date": "2026-06-24",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Grayslake, Illinois",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07673120"
    },
    {
      "nct_id": "NCT00613223",
      "title": "Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gliosarcoma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Vandetanib and Etoposide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Annick Desjardins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2008-02",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00613223"
    },
    {
      "nct_id": "NCT01828723",
      "title": "Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lipoatrophy",
        "Aging",
        "Wrinkles"
      ],
      "interventions": [
        {
          "name": "SVF",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Antria",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2013-04",
      "completion_date": "2015-01",
      "has_results": false,
      "last_update_posted_date": "2015-01-27",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 1,
      "location_summary": "Greensburg, Pennsylvania",
      "locations": [
        {
          "city": "Greensburg",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828723"
    },
    {
      "nct_id": "NCT00258349",
      "title": "Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Male Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2006-08",
      "completion_date": "2010-09",
      "has_results": true,
      "last_update_posted_date": "2014-06-02",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Des Moines, Iowa • Sioux City, Iowa + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00258349"
    },
    {
      "nct_id": "NCT03106038",
      "title": "Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Intraoperative Ureter Injury"
      ],
      "interventions": [
        {
          "name": "Nerindocianine for Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Li-Cor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "19 Years and older · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2017-04-26",
      "completion_date": "2018-11-19",
      "has_results": false,
      "last_update_posted_date": "2019-11-26",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03106038"
    },
    {
      "nct_id": "NCT04210115",
      "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Esophageal Squamous Cell Carcinoma (ESCC)",
        "Gastroesophageal Junction Carcinoma (GEJC)",
        "Esophageal Adenocarcinoma (EAC)"
      ],
      "interventions": [
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "leucovorin",
          "type": "DRUG"
        },
        {
          "name": "levoleucovorin",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 703,
      "start_date": "2020-02-28",
      "completion_date": "2026-06-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 19,
      "location_summary": "Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04210115"
    },
    {
      "nct_id": "NCT07784725",
      "title": "A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity or Overweight"
      ],
      "interventions": [
        {
          "name": "AZD6234",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2500,
      "start_date": "2026-08-19",
      "completion_date": "2029-05-21",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 33,
      "location_summary": "Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 30 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07784725"
    },
    {
      "nct_id": "NCT02286089",
      "title": "Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OpRegen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2015-04-01",
      "completion_date": "2031-01-31",
      "has_results": true,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02286089"
    },
    {
      "nct_id": "NCT07219368",
      "title": "A First-in-Human Single and Multiple Ascending Dose Study of MT-201",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "MT-201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirador Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 72,
      "start_date": "2025-10-08",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-10-26T20:57:33.027Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219368"
    }
  ]
}